IL6 and COVID-19: Our model shows that, in a situation with rapid, high, dysregulated IL-6 production – such as severe COVID-19 or a cytokine storm – an initial dose of either an anti-IL-6 or anti-IL-6R mAb inhibits IL-6 bioactivity.